SCHEMBL5755559

SCHEMBL5755559

CC(C)[C@@H](NS(=O)(=O)c1ccc2nc(Sc3ccccc3)sc2c1)C(=O)NO

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.52
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
MMP13 P45452 2/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
MMP9 P14780 1/20 0.50
HTT P42858 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
ALOX15 P16050 2/20 0.47
MMP12 P39900 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757303 0.91 MMP13 (0.55) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5755034 0.87 ALDH1A1 (0.55) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5756019 0.86 MAPT (0.53) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5756197 0.85 MMP13 (0.54) ALDH1A1GAAMMP13MMP1MMP2
SCHEMBL5755974 0.84 ALDH1A1 (0.55) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5755143 0.83 ALDH1A1 (0.56) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5754967 0.83 ALDH1A1 (0.53) TP53ALDH1A1GAAHPGDTSHR
SCHEMBL5757712 0.83 MMP13 (0.54) ALDH1A1GAAMMP13MMP1MMP2
SCHEMBL5758777 0.83 HTT (0.54) TP53ALDH1A1GAAMMP13MMP1
SCHEMBL5755888 0.81 ALDH1A1 (0.50) TP53ALDH1A1GAAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 TP53 2969/4885ALDH1A1 311/4885GAA 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.